Small Animal Clinical Pharmacology - CYF MEDICAL DISTRIBUTION

Index
A
α-adrenergic receptors 70, 71
α 1 -adrenergic receptors 73
α 2 -adrenoceptors 73
α-adrenoceptor agonists 143
α 1 -adrenoceptor agonists 96–97,
120–124
and ketamine combinations 105
α-adrenoceptor antagonists 73–74,
144
α 1 -adrenoceptor antagonists 471
α 2 -adrenoceptor antagonists 74, 124,
471
Abortifacient 541
Abortion
induction 534, 535, 537, 538, 541,
542
prevention 536
Absorbants 488–489
Absorption
dogs vs cats 47
half-life 2–3
physiological basis of 29–31
ACE inhibitors see Angiotensinconverting
enzyme (ACE)
inhibitors
Acemannan 279
Acepromazine 114–116
Acepromazine (ACP) 114–115, 116,
315
Acetaminophen see Paracetamol
(Acetaminophen)
Acetazolamide 571
Acetonide 263
Acetyl salicylic acid see Aspirin
Acetylcholine (ACh) 60–65
airway diameter regulation
458–459, 462
behavior-modification 127
inactivation 69
nicotinic receptors 9, 66
sedative action 114
vascular action 65
see also Muscarinic receptors;
Nicotinic receptors
Acetylcholinesterase 67
Acetylcysteine 466–467
Acetylpromazine 130–131
N-Acetyltransferase (NAT) 53–54
Aciclovir 9, 568
Actinomycin D 333, 336, 353–354
Activated charcoal 489
Active transport 29
Adenosine 8
Adenosine triphosphate 63
574
S-adenosyl methionine (SAMe) 494
Adrenal cortex
drugs acting on 520–524
physiology 519
Adrenal dysfunction
hyperadrenocorticism 517–524
hypoadrenocorticism 524–527
Adrenaline see Epinephrine
(Adrenaline)
Adrenergic agonists 459–461
see also α-adrenoceptor agonists;
α 2 -adrenoceptor agonists;
β 2 -adrenoceptor agonists
Adrenergic receptors 8, 69–70, 71,
73
Adrenocorticotrophic hormone
(ACTH) 519, 520, 521
Adrenoreceptor agonists 73, 78–81
Adrenoreceptor antagonists 73–74,
81–82
Adriamycin see Doxorubicin
Adverse drug reactions (ADRs) 41–58
augmented (type A) 41, 47–55
bizarre (Type B) 41
chronic (Type C) 41
classification 41–42
delayed (Type D) 41
diagnostic difficulties 43–44
end of treatment (Type E) 42
failure of treatment (Type F) 42
hypersensitivity 55–56
identification 46–47
incidence 42–46
postmarketing surveillance
(pharmacovigilance) 44–46
prescribing principles 25
reporting 44–46, 56–57
Australia 56
Canada 57
New Zealand 57
South Africa 57
UK 57
USA 57
vs adverse events (AEs) 41
see also specific drugs/drug classes
Aerosols, adrenergic agonists 459–460
Age
adverse drug reaction (ADRs) 50
influence on pharmacokinetics 18,
19
Aglepristone (RU534) 537–538
Agonists 6
Albaconazole 193–194, 238
Albendazole 204, 208, 238
Albuterol (salbutamol)
sulfate 460–461
Aldosterone antagonists 418–419
Alfacalcidol 508
Alfentanil 319, 324–325
Alkylating agents 340–348
Allopurinol 236–240
antiprotozoal dosages 239
caution in renal disease 53
drug interactions 240
azathioprine 272
cyclophosphamide 334
theophylline 462
receptors and ligands 9
selective toxicity 201
Allylamines 195
Aloe vera extracts 553–554
Alphaxalone (alphadolone) 96,
101–103
Alprazolam 134–136, 135
Aluminum hydroxide 482–483
Alveolar inhalational anesthesia
85–87
Alveolar ventilation 86
Amfetamines 133–134
Amikacin 173
Aminocridine 237
Aminocyclitols 170–173
Aminoglycosides 9, 77, 151, 155,
170–173
adverse effects 56, 171–172
antiprotozoal 239
cats, sensitivity of 48
caution/avoidance in renal and
hepatic disease 53
interactions 17, 188, 392, 448,
454
mechanism of action 9, 170–171
mechanism of resistance 171
ocular therapy 565
pharmacokinetics 171
therapeutic drug monitoring
(TDM) 37
see also Amikacin, Framycetin,
Gentamicin, Kanamycin,
Neomycin, Paromomycin,
Streptomycin, Tobramycin
Aminopenicillins 155, 162
Aminophylline 461–462
8-Aminoquinolone 237
Amiodarone 384, 427, 438–439
Amitraz 204, 222, 224–225
Amitriptyline 136, 136–138, 137
in pruritis 267
Amlodipine 384, 403, 404–405
emergency glaucoma treatment
571
Amorphous state 12